Table 3.
HPV prevalence at three mucosal sites (cervical, anal and oro-pharyngeal) stratified by genotype and known risk.
| LG patient samples (n = 129) | HG patient samples (n = 164) | ||||||
|---|---|---|---|---|---|---|---|
| Cervical (n = 44) | Anal (n = 41) | Oro-pharyngeal (n = 44) | Cervical (n = 56) | Anal (n = 52) | Oro-pharyngeal (n = 56) | ||
| 16 (p = 0.41) | 20 (45.5%) | 24 (58.5%) | 22 (50.0%) | 33 (58.9%) | 28 (53.8%) | 31 (55.4%) | |
| 31 (p = 0.49) | 10 (22.7%) | 10 (24.4%) | 13 (29.5%) | 14 (25.0%) | 10 (19.2%) | 12 (21.4%) | |
| High-risk (HR) & probable HR (PHR) | 33 (p = 0.55) | 8 (18.2%) | 9 (22.0%) | 10 (22.7%) | 9 (16.1%) | 6 (11.5%) | 14 (25.0%) |
| 53 (p = 0.083) | 6 (13.6%) | 10 (24.4%) | 5 (11.4%) | 5 (8.9%) | 12 (23.1%) | 3 (5.4%) | |
| 59 (p = 0.26) | 6 (13.6%) | 9 (22.0%) | 9 (20.5%) | 3 (5.4%) | 7 (13.5%) | 6 (10.7%) | |
| 45 (p = 0.40) | 7 (15.9%) | 11 (26.8%) | 7 (15.9%) | 6 (10.7%) | 4 (7.7%) | 4 (7.1%) | |
| 56 (p = 0.0004) | 5 (11.4%) | 7* (17.1%) | 7# (15.9%) | 2 (3.6%) | 1 (1.9%) | 2 (3.6%) | |
| 18 (p = 0.068) | 1 (2.3%) | 2 (4.9%) | 2 (4.5%) | 6 (10.7%) | 5 (9.6%) | 5 (8.9%) | |
| 66 (p = 0.0059) | 3 (6.8%) | 5 (12.2%) | 4 (9.1%) | 1 (1.8%) | 1 (1.9%) | 1 (1.8%) | |
| Othersa | 22 | 23 | 17 | 31 | 19 | 23 | |
| Low-risk (LR)b | 18 | 16 | 10 | 12 | 15 | 8 | |
| Undetermined-risk (UDR)c | 10 | 10 | 8 | 7 | 9 | 3 | |
| Total | 116 | 136 | 114 | 129 | 117 | 112 | |
*#prevalence of HPV56 was significantly higher in anal (p = 0.0198) and oro-pharyngeal (p = 0.0406) samples from LG patients (Fisher's exact test, two-tailed). Only the 9 most frequent HR-HPV and PHR-HPV subtypes have been included in the table for clarity. acumulative occurrences of the remaining 12 HR-HPV & probable HR-HPV subtypes (26, 35, 39, 51, 52, 58, 68, 69, 70, 73, 82 and IS39). bcumulative occurrences of 9 LR-HPV subtypes (6, 11, 40, 42, 54, 61, 72, 81 and CP6108). ccumulative occurrences of 7 UDR-HPV subtypes (55, 62, 64, 67, 71, 83 and 84).